Navigation Links
TorreyPines Therapeutics to Present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference
Date:2/26/2008

LA JOLLA, Calif., Feb. 26 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer of TorreyPines, will present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference in New York City on Tuesday, March 4th at 11:00 a.m., Eastern.

A webcast of Dr. Kurtz's presentation will be available live. You can access the webcast at: http://www.torreypinestherapeutics.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small molecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x158 212-845-4271

cjohnson@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: I
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2007 Results
2. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
6. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
9. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
10. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
11. Ocera Therapeutics Closes $35.5 Million Series C Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)... Advisory Committee on Climate Change (NACCC) thro...t in collaboration with the Vanuatu Meteorological... generated preliminary climate change and sea leve...he country’s SNC reporting to the United Nat...C). , Port Vila, Vanuatu...
(Date:11/27/2009)...ye test alternative is helping bring complete aut...oser for pharma-companies. It is a non-destructive... Sepha for use with blister packs and it has alre...rma-companies such as Sanofi-Avenis and Zydus-Cadi...improvements on the packaging line. Blisterscan ...
(Date:11/25/2009)... -- Biotech firm Replikins Ltd., which has analyze...mic through the prediction, outbreak, and progress...test biochemical analysis of the virus. The new da...u") virus has dropped from its peak of 3.7 (s.d. 4...ing of 2009 to resting non-epidemic levels this we...
(Date:11/25/2009)...- Cytochroma today announced the appointment of Pe...t will replace Mr. Ulrik Spork as the Novo A/S rep...Board members remains unchanged at six members. ,... the board and look forward to benefiting from his...o make progress in becoming a leading CKD-focused ...
Breaking Biology Technology:Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2
...., Nov. 3 Arno Therapeutics,Inc. (OTC Bulletin Bo...pany,focused on oncology therapeutics, today annou...cer of Arno, will present at the Rodman & Renshaw ...ber 10, 2008 at 2:00 PM EST in,the Kennedy I room ...,Berlin will provide a company overview and update...
...., Nov. 3 Metabolex, Inc., a,biopharmaceutical co...proprietary new medicines for the treatment of met... (MBX-2982 and MBX-8025) have been,recognized in W...able for,partnering" in their respective categorie...for type 2 diabetes, was recognized in the,metabol...
...resented during Renal Week 2008,November 4th throu...ael and LONDON, Nov. 3 Medgenics,(AIM: MEDG), is ...or its,Phase I/II clinical trial., The landmark P...pump,for providing sustained treatment of anemia i...y. The current trial is designed to assess the saf...
Other Biology Technology:Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 2Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 3Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 2Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 3Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 4Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 5
(Date:11/25/2009)...n,t have easy lives. In addition to mammalian immu...l enemies called bacteriophages, viruses that kill...till, bacteria and another class of microorganisms...onments such as deep-sea volcanic vents) manage ju...ilt-in defense system that helps protect them from...
(Date:11/25/2009)...etime, the heart pumps some 250 million liters of ...he muscle fibers of the heart have to be extremely...g Rottbauer, vice chair of the Department of Medic...n: Prof. Dr. H. A. Katus), has discovered a protei...llest muscular unit, the sarcomere. In cooperation...
(Date:11/24/2009)...tute (LRI) today named 12 new grant recipients for...e innovative work across a broad spectrum of lupus... novelty, and potential to drive scientific discov...plex disease of systemic lupus. , The 2009 grant... across the nation and include interdisciplinary a...
Breaking Biology News(10 mins):Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Protein can help cells or cause cancer Purdue researcher finds 9147 1Protein can help cells or cause cancer Purdue researcher finds 9147 2UTSA psychologist awarded 241 million for memory research 9144 1Playing it safe 9143 1
..., Va. An international team of scientists has pro...s water more efficiently than other rice crops. Pr...s Institute (VBI) has been working with colleagues...e Netherlands to identify, characterize and make u...ures of this important grain crop. The research, w...
...ana Tech faculty members, Dr. Sumeet Dua, an assis... Selmic, an assistant professor of electrical engi...ledge to help the U.S. Air Force and Department of...ities. , Duas project, called Automated Target De...ment of fast and accurate computer algorithms for ...
...ersity of Utah mathematicians have arrived at a ne...flows through sea ice a discovery that promises t...ect polar icepacks. , In the current issue of th...ssor Ken Golden and colleagues show that brine mov...iversal transport properties. , It means that al...
Other Biology News:HARDY rice: less water, more food 2HARDY rice: less water, more food 3Louisiana Tech researchers investigate tracking, sensors to assist Air Force 2Louisiana Tech researchers investigate tracking, sensors to assist Air Force 3Icy calculations on a hot topic 2Icy calculations on a hot topic 3
Rabbit Anti-Uncoupling Protein-2, aa 144-157 Polyclonal Antibody, Unconjugated from Calbiochem
Rabbit Anti-Human Janus Kinase 2 (JAK2) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
Mouse Anti-HSV-2 Glycoprotein G-2 Monoclonal Antibody, Unconjugated, Clone H1206 from Meridian Life Science, Inc.
Rabbit Anti-Phospho RNA Polymerase II (S5) Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products: